• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

群体药代动力学建模中的联合比例和加和残差误差模型。

Combined proportional and additive residual error models in population pharmacokinetic modelling.

机构信息

Department of Anesthesiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Pharmacokinetics, Toxicology and Targeting, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.

出版信息

Eur J Pharm Sci. 2017 Nov 15;109S:S78-S82. doi: 10.1016/j.ejps.2017.05.021. Epub 2017 May 13.

DOI:10.1016/j.ejps.2017.05.021
PMID:28512056
Abstract

INTRODUCTION

In pharmacokinetic modelling, a combined proportional and additive residual error model is often preferred over a proportional or additive residual error model. Different approaches have been proposed, but a comparison between approaches is still lacking.

METHODS

The theoretical background of the methods is described. Method VAR assumes that the variance of the residual error is the sum of the statistically independent proportional and additive components; this method can be coded in three ways. Method SD assumes that the standard deviation of the residual error is the sum of the proportional and additive components. Using datasets from literature and simulations based on these datasets, the methods are compared using NONMEM.

RESULTS

The different coding of methods VAR yield identical results. Using method SD, the values of the parameters describing residual error are lower than for method VAR, but the values of the structural parameters and their inter-individual variability are hardly affected by the choice of the method.

CONCLUSION

Both methods are valid approaches in combined proportional and additive residual error modelling, and selection may be based on OFV. When the result of an analysis is used for simulation purposes, it is essential that the simulation tool uses the same method as used during analysis.

摘要

简介

在药代动力学建模中,与比例或加性残差模型相比,通常更倾向于使用组合比例和加性残差模型。已经提出了不同的方法,但仍缺乏对这些方法的比较。

方法

描述了方法的理论背景。方法 VAR 假设残差的方差是统计上独立的比例和加性分量之和;这种方法可以用三种方式进行编码。方法 SD 假设残差的标准差是比例和加性分量之和。使用文献中的数据集和基于这些数据集的模拟,使用 NONMEM 对这些方法进行了比较。

结果

方法 VAR 的不同编码产生了相同的结果。使用方法 SD,描述残差的参数值低于方法 VAR,但结构参数及其个体间变异性的值几乎不受方法选择的影响。

结论

这两种方法都是联合比例和加性残差建模的有效方法,可以根据 OFV 进行选择。当分析的结果用于模拟目的时,模拟工具使用与分析期间相同的方法是至关重要的。

相似文献

1
Combined proportional and additive residual error models in population pharmacokinetic modelling.群体药代动力学建模中的联合比例和加和残差误差模型。
Eur J Pharm Sci. 2017 Nov 15;109S:S78-S82. doi: 10.1016/j.ejps.2017.05.021. Epub 2017 May 13.
2
Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.多柔比星的群体药代动力学:成人和 3 岁以上儿童 NONMEM 模型的建立。
Cancer Chemother Pharmacol. 2013 Mar;71(3):749-63. doi: 10.1007/s00280-013-2069-1. Epub 2013 Jan 13.
3
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.依法韦仑在未经筛选的HIV-1感染个体队列中的群体药代动力学。
Clin Pharmacokinet. 2005;44(8):849-61. doi: 10.2165/00003088-200544080-00006.
4
Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.群体药代动力学参数估计方法的评价。III. 单指数模型:常规临床药代动力学数据
J Pharmacokinet Biopharm. 1983 Jun;11(3):303-19. doi: 10.1007/BF01061870.
5
Assessment of type I error rates for the statistical sub-model in NONMEM.NONMEM中统计子模型的I型错误率评估。
J Pharmacokinet Pharmacodyn. 2002 Jun;29(3):251-69. doi: 10.1023/a:1020254823597.
6
A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.一个关于结构模型参数估计对患者报告给药时间误差敏感性的药代动力学案例研究。
J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):627-37. doi: 10.1007/s10928-015-9428-y. Epub 2015 Jul 26.
7
Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.阿波明的群体药代动力学:癌症患者和健康男性的荟萃分析。
Br J Clin Pharmacol. 2004 Aug;58(2):142-55. doi: 10.1111/j.1365-2125.2004.02111.x.
8
Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.群体药代动力学参数估算方法的评估。I. 米氏模型:常规临床药代动力学数据。
J Pharmacokinet Biopharm. 1980 Dec;8(6):553-71. doi: 10.1007/BF01060053.
9
ADVAN-style analytical solutions for common pharmacokinetic models.常见药代动力学模型的ADVAN式解析解。
J Pharmacol Toxicol Methods. 2015 May-Jun;73:42-8. doi: 10.1016/j.vascn.2015.03.004. Epub 2015 Apr 2.
10
Population pharmacokinetics meets microdialysis: benefits, pitfalls and necessities of new analysis approaches for human microdialysis data.群体药代动力学与微透析技术的结合:人类微透析数据新分析方法的优势、陷阱与必要性。
Eur J Pharm Sci. 2014 Jun 16;57:68-73. doi: 10.1016/j.ejps.2013.11.004. Epub 2013 Nov 15.

引用本文的文献

1
Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice.在临床实践中,将群体药代动力学建模与精准给药相结合的推荐方法。
Br J Clin Pharmacol. 2025 Apr;91(4):1064-1079. doi: 10.1111/bcp.16335. Epub 2024 Nov 21.
2
Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients With Cystic Fibrosis.囊性纤维化患者中头孢吡肟、美罗培南和哌拉西林-他唑巴坦的群体药代动力学建模
J Infect Dis. 2025 Feb 20;231(2):e364-e374. doi: 10.1093/infdis/jiae451.
3
Effect of Interindividual Variability in Metabolic Clearance and Relative Bioavailability on Rifampicin Exposure in Tuberculosis Patients with and without HIV Co-Infection: Does Formulation Quality Matter?
代谢清除率和相对生物利用度的个体间差异对合并或未合并HIV感染的结核病患者利福平暴露量的影响:制剂质量有影响吗?
Pharmaceutics. 2024 Jul 23;16(8):970. doi: 10.3390/pharmaceutics16080970.
4
Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power-law based pharmacokinetic modeling.预测肌肉内尼氯硝唑作为抗病毒药物的肺部暴露:基于幂律的药代动力学模型。
Clin Transl Sci. 2024 May;17(5):e13833. doi: 10.1111/cts.13833.
5
Tutorial on model selection and validation of model input into precision dosing software for model-informed precision dosing.模型选择和验证教程,用于将模型输入到精准给药软件中,以实现基于模型的精准给药。
CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1827-1845. doi: 10.1002/psp4.13056. Epub 2023 Oct 12.
6
Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg.健康受试者单剂量 400mg 伊马替尼的群体药代动力学模型研究。
Cancer Chemother Pharmacol. 2022 Aug;90(2):125-136. doi: 10.1007/s00280-022-04454-y. Epub 2022 Jul 14.
7
Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease.粪卟啉原 I 作为一种内源性生物标志物,可用于检测慢性肾脏病中 OATP1B 活性降低和消除途径的改变。
Clin Pharmacol Ther. 2022 Sep;112(3):615-626. doi: 10.1002/cpt.2672. Epub 2022 Jun 28.
8
Model-Based Equivalent Dose Optimization to Develop New Donepezil Patch Formulation.基于模型的等效剂量优化以开发新的多奈哌齐贴剂制剂
Pharmaceutics. 2022 Jan 20;14(2):244. doi: 10.3390/pharmaceutics14020244.
9
Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib.群体药代动力学建模与模拟以确定纳米粒索拉非尼相对于参比索拉非尼的最佳剂量。
Pharmaceutics. 2021 Apr 28;13(5):629. doi: 10.3390/pharmaceutics13050629.
10
Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients.验证一个围手术期人群因子 VIII 药代动力学模型在一大群小儿血友病 A 患者中的应用。
Br J Clin Pharmacol. 2021 Nov;87(11):4408-4420. doi: 10.1111/bcp.14864. Epub 2021 May 4.